Abstract
| Original language | English |
|---|---|
| Journal | Critical Reviews in Oncology/Hematology |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Keywords
- Radiotherapy
- Systemic compounds
- Toxicity
Cite this
Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity. / Arcangeli, Stefano; Jereczek-Fossa, Barbara Alicia; Alongi, Filippo; Aristei, Cynthia; Becherini, Carlotta; Belgioia, Liliana; Buglione, Michela; Caravatta, Luciana; D’Angelillo, Rolando Maria; Filippi, Andrea Riccardo; Fiore, Michele; Genovesi, Domenico; Greco, Carlo; Livi, Lorenzo; Magrini, Stefano Maria; Marvaso, Giulia; Mazzola, Rosario; Meattini, Icro; Merlotti, Anna; Palumbo, Isabella; Pergolizzi, Stefano; Ramella, Sara; Ricardi, Umberto; Russi, Elvio; Trovò, Marco; Sindoni, Alessandro; Valentini, Vincenzo; Corvò, Renzo.
In: Critical Reviews in Oncology/Hematology, 2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity
AU - Arcangeli, Stefano
AU - Jereczek-Fossa, Barbara Alicia
AU - Alongi, Filippo
AU - Aristei, Cynthia
AU - Becherini, Carlotta
AU - Belgioia, Liliana
AU - Buglione, Michela
AU - Caravatta, Luciana
AU - D’Angelillo, Rolando Maria
AU - Filippi, Andrea Riccardo
AU - Fiore, Michele
AU - Genovesi, Domenico
AU - Greco, Carlo
AU - Livi, Lorenzo
AU - Magrini, Stefano Maria
AU - Marvaso, Giulia
AU - Mazzola, Rosario
AU - Meattini, Icro
AU - Merlotti, Anna
AU - Palumbo, Isabella
AU - Pergolizzi, Stefano
AU - Ramella, Sara
AU - Ricardi, Umberto
AU - Russi, Elvio
AU - Trovò, Marco
AU - Sindoni, Alessandro
AU - Valentini, Vincenzo
AU - Corvò, Renzo
PY - 2018
Y1 - 2018
N2 - Clinical development and use of novel systemic agents in combination with radiotherapy (RT) is at nowadays most advanced in the field of treatment of solid tumors. Although for many of these substances preclinical studies provide sufficient evidences on their principal capability to enhance radiation effects, the majority of them have not been investigated in even phase I clinical trials for safety in the context of RT. In clinical practice, unexpected acute and late side effects may emerge especially in combination with RT. As a matter of fact, despite combined modality treatment holds potential for enhancing the therapeutic ratio, some concerns are raised from the lack of high-quality clinical data to guide the care of patients who are treated with novel compounds in conjunction with RT. The aim of this review is to provide, from a radio-oncological point of view, an overview of the most advanced combined treatment concepts for solid tumors focusing on treatment toxicity.
AB - Clinical development and use of novel systemic agents in combination with radiotherapy (RT) is at nowadays most advanced in the field of treatment of solid tumors. Although for many of these substances preclinical studies provide sufficient evidences on their principal capability to enhance radiation effects, the majority of them have not been investigated in even phase I clinical trials for safety in the context of RT. In clinical practice, unexpected acute and late side effects may emerge especially in combination with RT. As a matter of fact, despite combined modality treatment holds potential for enhancing the therapeutic ratio, some concerns are raised from the lack of high-quality clinical data to guide the care of patients who are treated with novel compounds in conjunction with RT. The aim of this review is to provide, from a radio-oncological point of view, an overview of the most advanced combined treatment concepts for solid tumors focusing on treatment toxicity.
KW - Radiotherapy
KW - Systemic compounds
KW - Toxicity
U2 - 10.1016/j.critrevonc.2018.11.006
DO - 10.1016/j.critrevonc.2018.11.006
M3 - Article
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -